Found 369 articles for: "Open Access"
FULL SUPPLEMENT: Tildrakizumab In Everyday Dermatology: Clinical Insights From Challenging Psoriasis Cases
October 2026 | Volume 25 | Issue 10 | Department | 435800s1 | Copyright © October 2026
Tildrakizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), a key cytokine in the pathogenesis of psoriasis. In the pivo...
Read MoreINDIVIDUAL ARTICLE: Tildrakizumab for Real-World Psoriasis Care: Clinical Lessons From Medically Complex and Underserved Patient Populations
October 2026 | Volume 25 | Issue 10 | Supplement Individual Articles | 435801s4 | Copyright © October 2026
Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23, has demonstrated durable efficacy and a favorable long-term safety profile in moderate-to-severe plaque p...
Read MoreFULL SUPPLEMENT: Ammonium Lactate for Xerotic Skin Conditions: Biomimetic Effects and Clinical Relevance
October 2026 | Volume 25 | Issue 10 | Department | 946300s1 | Copyright © October 2026
Xerosis is a common and clinically significant dermatologic concern, affecting patients across a broad spectrum of conditions, including atopic dermatitis, psoriasis, ichthyosis, and age- or environme...
Read MoreINDIVIDUAL ARTICLE: Ammonium Lactate in Clinical Practice: Optimizing Treatment of Xerotic and Hyperkeratotic Skin Conditions
October 2026 | Volume 25 | Issue 10 | Supplement Individual Articles | 946302s4 | Copyright © October 2026
Ammonium lactate is a well-established, time-tested dermatologic therapy with a substantial body of clinical evidence supporting its use inxerotic and hyperkeratotic skin conditions....
Read MoreINDIVIDUAL ARTICLE: Beyond Moisturization: Ammonium Lactate as a Biomimetic Regulator of Skin Barrier Function
October 2026 | Volume 25 | Issue 10 | Supplement Individual Articles | 946301s10 | Copyright © October 2026
The stratum corneum (SC) is essential for maintaining skin barrier integrity through coordinated interactions between corneocytes, intercellular lipids, and natural moisturizing factors (NMFs). L...
Read MoreFundamentals of Hyperpigmentation Disorders: Causes, Concerns, and Treatment Strategies, Particularly in Skin of Color Patients
October 2026 | Volume 25 | Issue 10 | Original Article | 926 | Copyright © October 2026
Background: Pigmentary disorders, including hyperpigmentation, are among the most common dermatologic diagnoses in individuals with skin of color (SOC), particularly individuals ...
Read MoreNordic European Countries Atopic Dermatitis (NECAD) I: Importance of Concordance With Skincare for Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Original Article | 949 | Copyright © October 2026
Background: Atopic dermatitis (AD) is a chronic disease with a dysfunctional skin barrier, requiring continuous management to reduce symptoms and prevent flares. Topical treatmen...
Read MoreThe Essential Role of Topical Targeted Therapy in Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Original Article | 898 | Copyright © October 2026
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by immune dysregulation, epidermal barrier dysfunction, microbiome imbalance, pruritus, and xero...
Read MoreHistological Analysis Shows That a Moisturizer Formulated for Dermatoporosis Increases Elastin Content and Improves Skin Elasticity
October 2026 | Volume 25 | Issue 10 | Original Article | 962 | Copyright © October 2026
Background: Dermatoporosis involves age-related alterations in dermal structure and cellular function, including changes in collagen, elastin, and markers of skin senescence. Cha...
Read MoreFULL SUPPLEMENT: The Hidden Burden of Topical Corticosteroids: Integrating Literature, Prescribing Information, and Real-World Evidence
November 2026 | Volume 25 | Issue 11 | Department | 104190s1 | Copyright © November 2026
INDIVIDUAL ARTICLE: Cutaneous and Systemic Adverse Events Associated With Topical Corticosteroid Use: A Targeted Literature Review
November 2026 | Volume 25 | Issue 11 | Supplement Individual Articles | 10419s4 | Copyright © November 2026
Background: Topical corticosteroids (TCS) have been used to treat chronic inflammatory skin conditions since initial approval in 1950, which was followed by reports of cutaneous an...
Read MoreINDIVIDUAL ARTICLE: Topical Corticosteroid Approved Labeling in the US: A Modern Inter- and Intra-Product Analysis
November 2026 | Volume 25 | Issue 11 | Supplement Individual Articles | 10424s11 | Copyright © November 2026
Background: A wide variety of prescription-strength topical corticosteroids (TCS) have been commercially available for many decades. Product labels often vary, reflecting inconsist...
Read MoreINDIVIDUAL ARTICLE: Real-World Study of Topical Corticosteroid-Associated Adverse Events in the FDA Adverse Event Reporting System
November 2026 | Volume 25 | Issue 11 | Supplement Individual Articles | 10425s21 | Copyright © November 2026
Background: Corticosteroids (CS) and topical CS (TCS) are widely used, yet the real-world burden and reporting patterns of associated adverse events (AEs) remain incompletely chara...
Read MoreFULL SUPPLEMENT: The Role of IL 31 Inhibition in Atopic Dermatitis
September 2026 | Volume 25 | Issue 9 | Department | 154710s1 | Copyright © September 2026
Atopic dermatitis and prurigo nodularis represent the two most burdensome pruritic inflammatory skin diseases encountered in clinical dermatology. While distinct in morphology, chronicity, and epidemi...
Read MoreINDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab
September 2026 | Volume 25 | Issue 9 | Supplement Individual Articles | 015471s2 | Copyright © September 2026
Interleukin-31 (IL-31) is a central mediator in atopic dermatitis (AD) and prurigo nodularis (PN), functioning both as the principal pruritogeniccytokine, driving itch through direct...
Read MoreFULL SUPPLEMENT: Real-World Split-Face Case Series of a Phyto Polydeoxyribonucleotide (PDRN) Serum in Integrative Skincare
September 2026 | Volume 25 | Issue 9 | Department | 15490s1 | Copyright © September 2026
Inflammation and photodamage are largely considered the leading contributors to premature skin aging as they lead to decreased collagen content in the skin. Collagen, the most abundant protein in the ...
Read MoreINDIVIDUAL ARTICLE: Real-World Cases Using Phyto Polydeoxyribonucleotide (PDRN) Serum
September 2026 | Volume 25 | Issue 9 | Supplement Individual Articles | 15491s2 | Copyright © September 2026
Background: Integrative skincare refers to a clinician-directed regimen that combines aesthetic procedures with appropriate post-procedure skincare. The novel phyto polydeoxyribo...
Read MoreSafety and Tolerability of Facial Skincare in Children and Adolescents: Clinical Testing and Multigenerational Insights
September 2026 | Volume 25 | Issue 9 | Original Article | 807 | Copyright © September 2026
Background: Pediatric and adolescent interest in facial skincare is increasing, often driven by social media and early exposure to adult-formulated products....
Read MoreA Novel Moisturizer Formulated With Micronized Centella asiatica and Mandelic Acid Improves Mature, Crepey Skin
September 2026 | Volume 25 | Issue 9 | Original Article | 833 | Copyright © September 2026
Background: Dermatoporosis is a condition of fragile, aging skin that manifests as altered pH, wrinkles, laxity, easy bruising, and hyperpigmentation. This study evaluated effica...
Read MoreFULL SUPPLEMENT: Research on Generalized Pustular Psoriasis
August 2026 | Volume 25 | Issue 8 | Department | 63120 | Copyright © August 2026
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
